background
patient
pediatr
cancer
higher
risk
morbid
mortal
respiratori
viral
infect
patient
popul
object
investig
caus
virus
respiratori
infect
burden
among
patient
pediatr
cancer
lebanon
studi
design
nasopharyng
swab
along
clinic
demograph
data
collect
patient
pediatr
cancer
present
febril
episod
upper
respiratori
tract
symptom
total
nucleic
acid
extract
specimen
follow
realtim
pcr
analysi
target
respiratori
virus
estim
frequenc
infect
result
obtain
nasopharyng
swab
patient
pediatr
cancer
mean
age
year
realtim
pcr
confirm
viral
infect
swab
among
respiratori
virus
detect
sever
virus
cocircul
within
period
respiratori
syncyti
viru
rsv
common
follow
parainfluenza
viru
piv
influenza
type
b
human
metapneumoviru
human
coronaviru
hcov
coinfect
detect
subject
involv
rsv
one
virus
strong
correl
found
piv
flu
influenza
type
rsv
hcov
incid
coinfect
rsv
associ
lower
respiratori
tract
infect
nasal
congest
bronchiti
bacteremia
hcov
associ
bronchiol
rhinoviru
associ
hospit
admiss
conclus
patient
pediatr
cancer
high
burden
respiratori
viral
infect
high
incid
coinfect
molecular
diagnost
improv
manag
febril
episod
reduc
antibiot
use
k
e
w
r
coinfect
patient
pediatr
cancer
preval
realtim
pcr
respiratori
tract
infect
viru
infect
j
med
virol
wileyonlinelibrarycomjournaljmv
immunocompromis
patient
cancer
hematopoiet
stem
cell
transplant
higher
risk
respiratori
infect
singl
mix
respiratori
virus
frequent
detect
acut
respiratori
symptom
defect
innat
adapt
immun
coupl
damag
mucos
membran
frequent
exposur
healthcar
environ
contribut
increas
morbid
mortal
respiratori
infect
patient
healthi
children
respiratori
virus
usual
confin
upper
respiratori
tract
immunocompromis
patient
progress
lower
respiratori
tract
frequent
fear
complic
despit
advanc
cancer
therapi
outcom
last
decad
respiratori
viral
infect
complic
frequent
barrier
success
antineoplast
treatment
respiratori
infect
major
caus
febril
episod
patient
pediatr
cancer
patient
often
initi
broadspectrum
antibiot
cover
seriou
bacteri
diseas
lead
unnecessari
increas
exposur
antibiot
potenti
emerg
antibiot
resist
accur
respiratori
viral
diagnosi
earli
access
treatment
improv
outcom
allow
prompt
initi
infect
control
measur
limit
antibiot
use
molecular
diagnost
assay
respiratori
viru
detect
identif
becom
increasingli
popular
outperform
tradit
viral
detect
method
antigen
detect
cell
culturebas
assay
term
speed
effici
specif
sensit
altogeth
fact
highlight
need
surveil
studi
util
molecular
diagnost
tool
elucid
role
viral
pathogen
respiratori
infect
risk
factor
outcom
epidemiolog
studi
respiratori
viral
infect
patient
pediatr
cancer
lowresourc
set
scarc
main
purpos
studi
screen
viral
etiolog
agent
associ
risk
factor
complic
respiratori
infect
patient
pediatr
cancer
lebanon
address
joint
need
surveil
studi
use
molecular
diagnost
tool
addit
studi
respiratori
infect
develop
countri
extract
control
screen
exclud
crosscontamin
extract
flu
aposit
sampl
subtyp
via
realtim
pcr
use
cdcestablish
protocol
rsvposit
sampl
subtyp
convent
pcr
follow
gel
electrophoresi
use
rsva
rsvb
primer
specif
g
gene
hypervari
region
univari
regress
analysi
perform
determin
associ
viral
monoand
coinfect
variabl
outcom
includ
demograph
hospitalicu
admiss
lower
respiratori
tract
infect
lrti
clinic
symptom
bronchiti
fever
mechan
ventil
nasal
congest
respiratori
distress
vomit
neutropenia
absolut
neutrophil
count
anc
lymphopenia
absolut
lymphocyt
count
test
odd
ratio
comput
test
associ
categor
variabl
variabl
statist
associ
sever
outcom
univari
model
includ
multivari
logist
regress
use
backward
select
method
signific
level
less
requir
covari
stay
model
odd
ratio
estim
p
valu
test
variabl
monitor
adjust
age
sex
similarli
correl
analysi
variabl
also
includ
correl
coeffici
calcul
measur
strength
relationship
differ
variabl
test
p
valu
consid
signific
statist
analysi
perform
use
sa
softwar
studi
period
febril
episod
record
individu
patient
median
age
patient
year
iqr
year
patient
male
univari
analysi
use
assess
associ
demograph
variabl
clinic
find
respiratori
virus
arti
tabl
children
younger
year
significantli
higher
risk
develop
respiratori
distress
age
year
p
cl
older
year
p
cl
neutropenia
anc
identifi
risk
factor
hospit
admiss
p
cl
statist
signific
associ
observ
respect
sex
cancer
type
treatment
lymphopenia
antivir
drug
administr
test
variabl
type
cancer
receiv
anticanc
drug
neutropenia
lymphopenia
associ
increas
risk
coinfect
addit
presenc
viral
coinfect
seem
correl
record
clinic
symptom
tabl
tabl
variabl
analyz
via
multivari
logist
regress
analysi
select
method
backward
elimin
wherebi
p
valu
requir
covari
stay
model
children
age
year
older
year
lower
odd
respect
respiratori
distress
younger
year
p
correl
analysi
show
rsv
r
p
figur
studi
period
patient
repeat
febril
episod
often
led
detect
viru
es
associ
first
episod
need
vaccin
effect
drug
commonli
circul
viral
pathogen
limit
unnecessari
administr
antivir
antibacteri
best
manag
isol
precaut
infect
patient
substanti
subset
studi
popul
coinfect
multipl
virus
find
associ
interv
specimen
collect
day
febril
neutropenia
children
mix
malign
similar
rate
respiratori
viral
infect
children
leukemia
mix
malign
report
usa
germani
finland
chile
contrast
spain
respiratori
viral
infect
detect
patient
cancer
viral
infect
monoinfect
mention
studi
rsv
rhv
flu
commonli
detect
virus
infant
highrisk
preterm
chronic
ill
rsv
neutral
monoclon
antibodi
includ
fdaapprov
palivizumab
effect
prophylaxi
remain
expens
develop
countri
emerg
rsv
variant
resist
palivizumab
concern
highlight
need
therapeut
option
report
prolong
rsv
shed
persist
day
case
